Introduction
Outcome after hematopoietic stem cell transplantation (HSCT) depends on a diverse set of biomedical factors including underlying disease, stage of disease at the time of transplantation, preparative regimens (myeloablative versus non-myeloablative), stem cell source, HLA disparity and demographic characteristics. 1 More recently a number of psychological variables have been added to the list of factors affecting outcome. As the literature on psychosocial variables affecting HCST survival grows, it also reveals the complex interrelationships between the psychological and biological determinants of the outcome. Thus, long-term functional recovery of stem cell transplant recipients may not only depend on the traditional clinical and laboratory variables, but also on behavioral factors. Previous reviews have concluded that neither depressed mood nor social support affect transplant outcomes, 2 and others have shown that psychological coping has no influence on cancer survivorship. 3 Such reports have added to skepticism regarding the relationship between behavioral variables and outcome. However, new data need to be integrated with the existing literature into a comprehensive review. We will attempt to evaluate the current status of studies focusing on the impact of pretransplant negative or positive emotional profiles on the survival of stem cell transplant recipients. If adverse psychological risk factors influencing survival are thus prospectively identified, then pharmacological and/or behavioral intervention may be called for to improve the clinical outcome.
Review of current literature
We searched MEDLINE and PsycINFO to September, 2005 for English language, peer-reviewed studies, which investigated the effect of psychosocial variables on survival after HSCT. In this literature search, we recovered 19 published reports. To assess the strength of these studies, we used three methodological criteria, two of which Petticrew et al. 3 implemented in their review. In our review, we place more weight on (1) prospective rather than cross-sectional or retrospective study design, (2) multivariate analyses to adjust for confounding medical and demographic variables and (3) the use of validated psychological measurements, such as the Beck Depression Inventory-II. 4 This third criterion stems from the fact that the field is hampered by the lack of consensus about how to assess and quantify key psychological variables in the HSCT population. The difficulty in standardizing assessment is partly due to the multiple parameters inherent in evaluating psychological functioning before, during and after HSCT: who should do the evaluating, by what modality, how close in time to transplant beforehand, how often during and after hospitalization, and how to account for medical status that might affect mood assessment (see Table 1 ). This lack of consensus justifies the establishment of consortia to study the validity and reproducibility of these assessment methods, and lay the groundwork for future hypothesisdriven intervention studies.
Negative emotions and survival
The relationship of negative emotion to survival has been investigated in 15 out of the 19 studies, comprising 1 806 patients. Negative emotions, as investigated in this group of studies, vary in accordance with the ways investigators have attempted to measure them. As shown in Tables 2 and 3,  the negative emotions encompass major and minor depression (as assessed by Diagnostic and Statistics Manual of  Mental Disorders Fourth Edition (DSM-IV) 24 criteria), dysphoric mood (as assessed by the Profile of Mood States (POMS) 25 ), depressive traits (as assessed by the Depression subscale of the Minnesota Multiphasic Personality Inventory (MMPI) 26 ) and depressive symptomatology (as assessed by the Composite International Diagnostic Interview (CIDI), 27 Hospital Anxiety and Depression Scale (HADS), 28 General Health Questionnaire -12 (GHQ-12); 29 Beck Depression Inventory-II (BDI-II) 4 ) and brief self-report questionnaires created by investigators.
As indicated in the column 'Factors without influence on survival' in Table 2 , five studies, 5-9 using psychometrically validated self-report inventories or structured interviews, found no statistical relationship between negative emotion and survival. One of these studies, 9 which included a mixed prospective and retrospective sample, should be interpreted with caution. The other four were prospective studies, [5] [6] [7] [8] although only one of these four studies 6 included negative emotion in the multivariate analysis. In addition, three of these four prospective studies [7] [8] [9] contained small sample sizes (mean n ¼ 45), which might have compromised the statistical power to detect the effects; the remaining two larger studies (n4110) 5, 6 employed psychometrically validated measures of depressive symptomatology, thus lending credence to their findings. Nevertheless, only one of these studies 6 included depressive symptomatology in their multivariate analysis, and failed to show negative influence of depressed mood on survival.
To the contrary, as indicated in the column 'Disadvantageous prognostic factors' in Table 3 , seven studies [14] [15] [16] 18, 19, 22, 23 reported a negative relationship between depressive symptomatology and survival: those with more depressive symptomatology had shorter survival. Out of these seven studies, two studies employed non-validated psychological measures retrospectively; 22,23 the remaining five were prospective studies that included depressed mood in the multivariate analysis. These five studies are summarized below:
Study by Prieto et al.
14
This study, consisting of 199 patients and using DSM-IV criteria to assess depression, found major depression during HSCT admission to be predictive of poor survival at 1 and 3 years after transplantation. This relationship no longer was significant for survival at 5 years owing to the small number of patients at risk in the later years.
Study by Hoodin et al.
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This study employed robust statistical methodology, and a psychometrically validated measure of depressive sympto- Table 1 Multiple parameters inherent in evaluating psychological functioning before, during, and after HSCT: challenges to standardizing psychological assessment
Dimensions
Options for consideration Psychological variables in stem cell transplantation F Hoodin et al Table 2 Survival analyses showing no effect for negative or positive moods This study with a sample of 193, found that patients reporting symptoms consistent with 'depressive syndrome' at their 6-month follow-up had a threefold greater risk of mortality in the following 6 months. The patient self-reports of depression were verified by chart review by a blind assessor. 
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This study, consisting of a sample of 72 patients, found shorter survival among patients with depressive symptoms (as measured by the POMS) at the 3-and 8-month followups for males, but no such relationship at the 1-and 3-year follow-ups. The statistical validity of this study was compromised by inclusion of many prognostic factors in the regression models despite a relatively small sample size. In summary, five studies to date found no relationship between pre-transplant depressive symptoms and survival, four in univariate analyses and one in multivariate analyses. On the other hand, seven studies reported shorter survival in patients with depressive symptoms, six in multivariate analyses. In addition, three studies revealed a time-dependent effect such that depressive symptomatology was more likely to affect survival closer in time to when symptoms were assessed.
Interestingly, in contrast to the studies reporting null effects of depressive symptoms on survival, the majority of studies reporting deleterious effects employed multivariate analyses that controlled for potential confounding influences of biomedical and other psychosocial variables on HSCT survival. These multivariate techniques can and do correct statistically for what would otherwise be a significant limitation in all of these studies: the inability of the investigators to manipulate the independent variables, depressed or optimistic mood, in randomized, controlled, double-blind designs.
Positive emotions and survival
The relationship of positive emotion to survival has been investigated in five out of the 19 studies, comprising 494 patients. Positive emotions, as they have been investigated in these studies, include 'optimism' (as indicated by patient self-report of optimistic expectations for transplant outcome 17 ), 'hopefulness' (as indicated by the Jalowiec Coping Scale 31 ) and 'fighting spirit' (as indicated by the Ulm Coping Manual (UCM), 20 or Mental Adjustment to Cancer Scale (MAC) 32 ). Although these terms are not interchangeable, they describe a cognitive style that is positive with respect to HSCT. The studies investigating optimistic cognitive styles found longer survival in patients with more optimism 17 and hopefulness 21 in multivariate analyses. The contradictory evidence for fighting spirit is possibly due to the limitations of small sample size and study design. Pre-transplant optimistic expectations for transplant outcome (not 'trait optimism' -an abiding personality characteristic that does not vary by life situation) displayed a time-dependent effect: a positive influence on 2-month survival but not long-term survival. 17 Although pretransplant optimism was assessed by an investigatorconstructed questionnaire, this large (n ¼ 313) prospective study indicated the significance of optimism on short-term survival. Another positive emotion studied by Molassiotis et al., 21 'hopefulness', was also suggested as a positive prognostic factor in a small (n ¼ 31) earlier study.
Fighting spirit 7, 9, 30 When 'fighting spirit' was assessed using the Mental Adjustment to Cancer Scale (MAC), it was not correlated with survival in two studies (n ¼ 42 and 56): one multivariate and prospective, 7 the other utilizing univariate analysis only in a mixed prospective and retrospective sample. 9 However, when 'fighting spirit' was assessed by the Ulm Coping Manual (UCM) in a prospective study, it was positively correlated with survival 20 in multivariate analysis (n ¼ 52).
In summary, three studies 17, 20, 21 found positive emotions to be correlated with longer survival, and two 7, 9 found no such correlation. However, all but one employed small sample size, and the larger study 17 documented a shortterm survival benefit. Thus evidence for the effects of positive emotions on HSCT outcome is very limited, hampered by small sample sizes that restrict confidence in statistical analyses, and by major differences across studies in how the positive emotions were measured.
What is important: positive or negative emotion?
Our previous review reported on the lack of good data showing a correlation of negative emotions and survival. 2 In the 3 years since then, several reports have provided stronger evidence of the deleterious effects of pre-transplant negative emotion: shorter survival. In contrast to the earlier studies, these recent reports followed more patients for longer follow-up periods with two major benefits: (a) permitting multivariate analyses to control statistically for confounding biomedical and psychosocial factors; (b) adjusting for a major challenge endemic to HSCT outcome studies: high attrition owing to morbidity and mortality.
Negative emotion also appears to affect quality of life after transplantation. In a longitudinal study of 319 transplant recipients with a follow-up of 94 survivors to 5 years after transplantation, pre-transplant clinical depression was significantly correlated with patients' slower physical recovery and higher medical risk. 33 Similarly, Loberiza et al. 18 reported HSCT recipients who had more depressive symptoms 6 months post transplant were more likely to be taking medications related to HSCT, less likely to be working, less likely to evaluate their health as good to excellent, or to describe their lives as returned to normal at 12 months post-HSCT. In sum, the HSCT literature is consistent with the broader literature which implicates depressed mood as an independent risk factor for all-cause mortality 34 and long-term risk for disability. 35 If depressive syndromes might influence outcome after HSCT, what mechanisms may be involved in this association? As indicated in Table 4 , one set of potential mediating mechanisms is indirect: depressed individuals are hypothesized to have less determination and involvement in one's care, 17 poorer adherence to treatment, lower availability of tangible social support and higher threshold for seeking medical evaluation of symptoms. 18 Another set of indirect mediating mechanisms is that depressed individuals are hypothesized to have poorer health behaviors (nutrition, sleep, exercise), and a higher likelihood of substance abuse and smoking, all of which have negative ramifications on organ systems. 36 A third, more direct yet highly speculative mechanism is depressed individuals display elevated proinflammatory cytokines, 36 and less efficient response to injury or infection. [37] [38] [39] [40] [41] [42] Alternatively, depression or optimism may indirectly reflect the patient's morbidity or treatment toxicity. All these pathways are speculative and yet to be evaluated in HSCT recipients.
Role of psychological evaluation in HSCT patients and what to look for
Improvement of the outcome of HSCT is not dependent on advancement from a single discipline within the transplant team. Contribution by each team member is necessary for overall improvement of outcome. This review provides some empirical evidence that psychosocial status of the patients can influence the outcome. Considering all the available data, it seems imperative that transplant teams should include psychological evaluation in the pre-transplant workup. This evaluation should assess for negative emotions as they may well affect the long-term outcome. However, the potential short-term impact of positive emotions such as optimism about transplant cannot be ignored.
We recommend a full pre-transplant clinical interview (along lines suggested by Knight 43 ) assessing for DSM-IV criteria for Mood Disorders and psychiatric disorders, psychological distress, marital and family distress, coping and social support and potential for non-adherence. To avoid the overdiagnosis of depression that may result from counting symptoms of anorexia and fatigue that may be a direct result of the disease process itself or its treatment, and to avoid the underdiagnosis of depression that may result from omitting counting those symptoms, some investigators 14 advocate the Memorial-Sloan-Kettering Cancer Center-modified DSM-IV approach 44 of omitting anorexia and fatigue, and decreasing the number of depressive criteria that must be present (from five to four) to qualify for DSM-IV diagnosis.
In addition to the clinical interview, brief self-administered instruments with good reliability and validity should be used, such as the Center for Epidemiological Studies Depression Scale (CESD), 45 or the Beck Depression Inventory-II, 4 which have defined score ranges as indicative of mild, moderate or severe depression. Instruments such as the Profile of Mood States 25 with much less robust testretest reliability would be useful for assessing reactive distress, but should not be relied upon to identify clinical depression. Each of these brief self-report measures can be completed in less than 10 min.
For assessing optimism about transplant, a promising option is a questionnaire devised by Lee et al., 17 consisting of two questions on a 5-point Likert Scale from 'strongly agree' to 'strongly disagree'. Patients are categorized as having 'high optimism' about transplant if they endorse strong agreement with 'I am optimistic that my transplant will go well', and strong disagreement with 'If anything can go wrong with my transplant it will'. Lee et al. 17 found that patients with high optimism assessed this way have a significantly better short-term outcome than patients who provide other response combinations to these questions. An alternative assessment of generalized optimism would be the six-item Life Orientation Test-Revised, 46 shown to be modestly related to confidence of remaining cancer-free in breast cancer patients, and predictive of well-being 5-13 years after surgery. 47 
Pre-transplant psychological profiling
Based on assessment of depressive symptomatology and optimistic expectations for transplant, patients may potentially fall into four categories, each with implications for further assessment or intervention. 48 with the goal of reducing depression and other forms of illness-related distress. 49 For example, a cognitive-behavioral stress management group intervention (incorporating emotional expression, cognitive restructuring, and training in relaxation, assertiveness, conflict resolution and coping skills) was associated with decreases in depression in a sample of early-stage breast cancer. 50 Cognitive Behavior Therapy is a therapeutic approach well suited to the HSCT patient: it is goaloriented, problem-focused in the here-and-now, and uses a range of cognitive and behavioral techniques to change thinking, mood and behavior. 51 Hence, in going forward with transplant in a candidate with clinical depression, transplant teams should consider adding individual psychological intervention, as well as psychiatric consultation if indicated, to the treatment protocol.
Depressive symptomatology; high optimistic expectations about transplant This is not a very likely category of patients. Patients who appear stoic, accepting, philosophical or simply trusting of the transplant team, might convey optimism about transplant. However, this presentation would not necessarily indicate the absence of clinically significant depression. Without formal psychological assessment, this concealed clinical depression may otherwise evade detection, and strategic opportunities for intervention may be missed.
To facilitate tracking patients' psychological status, we recommend screening using self-administered tools at regular intervals throughout the transplant hospitalization and until at least 100 days thereafter. Such screening has demonstrated utility in improving detection of depression, anxiety, and post-traumatic stress disorder in HSCT patients. 52 Because systematic repeated screening also permits comparing patients' subsequent scores to their own pre-transplant baseline and not only to population norms, transplant teams may be alerted thus to significant changes in mental and emotional status more efficiently than if they were to rely on informal self-or family-report alone.
Practical psychological intervention in HSCT patients
Psychologists in the transplant team are challenged with developing clinical intervention approaches that are acceptable to patients while they are struggling with medical treatment demands and complications. Thus, one approach could be a system of behavioral intervention delivered in frequent brief (20-30 min) individual sessions along the lines of Kuchler et al. 53 not only during hospitalization for HSCT, but also integrated with outpatient visits. Another approach could involve frequent brief telephone or teleconference sessions 43 to provide outreach to the patient whose residence is geographically distant from the transplant center or whose physical status poses significant barriers to attending sessions out of the home. All approaches could be integrated if appropriate with customized educational workbooks such as that piloted by Trask et al., 54 which contained instruction in relaxation techniques, problem-solving strategies and ways to challenge negative thinking and so improve mood. In some clinical situations, psychopharmacological intervention may be needed. However, drug interaction with immunosuppressive and antimicrobial agents may pose additional risk of organ toxicity. A detailed discussion of psychopharmacology in stem cell transplantation is beyond the scope of this review.
Conclusion
For the clinicians pondering whether pre-and peritransplant psychological evaluation is needed, and whether Psychological variables in stem cell transplantation F Hoodin et al behavioral clinicians should participate in providing transplantation care, our conclusion is in the affirmative. Profiling patients according to optimism about transplant and depressive symptomatology can suggest a practical approach to psychological intervention. However, consortia should be formed to define and evaluate pragmatics of assessment and intervention (timing, assessment tools, personnel) in multisite clinical trials to ascertain the degree to which they contribute to improving the overall outcome of HSCT in patients whose depressive symptomatology puts them at increased risk for mortality. For the present, psychological assessment and intervention along with psychiatric consultation no doubt comprise an important component of optimal patient care that can improve quality of life for transplant survivors.
